Literature DB >> 19701074

Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel.

Jinru Shia1, Laura H Tang, Efsevia Vakiani, Jose G Guillem, Zsofia K Stadler, Robert A Soslow, Nora Katabi, Martin R Weiser, Philip B Paty, Larissa K Temple, Garrett M Nash, W Douglas Wong, Kenneth Offit, David S Klimstra.   

Abstract

The utility of immunohistochemical detection of DNA mismatch repair proteins in screening colorectal cancer for hereditary nonpolyposis colorectal cancer (HNPCC) is being widely investigated. Currently, in both research and clinical settings, a 4-antibody panel that includes the 4 most commonly affected proteins (MLH1, MSH2, MSH6, and PMS2) is being used generally. On the basis of the biochemical properties of these proteins, we hypothesized that a 2-antibody panel, comprising MSH6 and PMS2, would be sufficient to detect abnormalities in all 4 proteins. We tested this hypothesis on a series of 232 colorectal carcinoma samples derived from 2 patient cohorts: (1) a prospectively accrued series of patients who were judged to carry a higher-than-average risk for HNPCC based on the revised Bethesda guidelines (n=190); and (2) a retrospective series of patients who were 40 years of age or younger (n=42). Immunohistochemical stains were regarded as negative (protein lost), when there was no nuclear labeling in tumor cells (with positive internal control). Overall, 70 of the 232 tumors demonstrated loss of at least one protein. The most common abnormality was concurrent loss of MLH1 and PMS2 (observed in 17% of the cases), followed by concurrent loss of MSH2 and MSH6 (6%). All MLH1 and MSH2-abnormal cases were also abnormal for PMS2 and MSH6, respectively, whereas 9 of 50 (18%) PMS2 and 6 of 20 (30%) MSH6-abnormal cases showed only isolated loss of PMS2 or MSH6 (with normal staining for MLH1 and MSH2). As such, our findings provide evidence that a 2-antibody panel (PMS2 and MSH6) is as effective as the current 4-antibody panel in detecting DNA mismatch repair protein abnormalities. Such a cost-effective approach carries significant implication, as immunohistochemistry is being widely used as first-line screening for HNPCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19701074     DOI: 10.1097/PAS.0b013e3181b15aa2

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  48 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline.

Authors:  Scott M Weissman; Randall Burt; James Church; Steve Erdman; Heather Hampel; Spring Holter; Kory Jasperson; Matt F Kalady; Joy Larsen Haidle; Henry T Lynch; Selvi Palaniappan; Paul E Wise; Leigha Senter
Journal:  J Genet Couns       Date:  2011-12-14       Impact factor: 2.537

3.  Lower prevalence of Lynch syndrome in colorectal cancer patients in a Japanese hospital-based population.

Authors:  Kensuke Kumamoto; Hideyuki Ishida; Okihide Suzuki; Yusuke Tajima; Noriyasu Chika; Koki Kuwabara; Keiichiro Ishibashi; Katsuharu Saito; Koji Nagata; Hidetaka Eguchi; Junichi Tamaru; Takeo Iwama
Journal:  Surg Today       Date:  2015-08-07       Impact factor: 2.549

Review 4.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

5.  Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome.

Authors:  Rachel Pearlman; Sigurdis Haraldsdottir; Albert de la Chapelle; Jon G Jonasson; Sandya Liyanarachchi; Wendy L Frankel; Thorunn Rafnar; Kari Stefansson; Colin C Pritchard; Heather Hampel
Journal:  J Med Genet       Date:  2019-03-15       Impact factor: 6.318

6.  Mismatch repair system in endometriotic tissue and eutopic endometrium of unaffected women.

Authors:  Tiziana Grassi; Angelo Calcagno; Stefania Marzinotto; Ambrogio P Londero; Maria Orsaria; Gioia N Canciani; Carlo Alberto Beltrami; Diego Marchesoni; Laura Mariuzzi
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

7.  Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications.

Authors:  Aziz Zaanan; Katy Meunier; Fatiha Sangar; Jean-François Fléjou; Françoise Praz
Journal:  Cell Oncol (Dordr)       Date:  2011-04-12       Impact factor: 6.730

8.  Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer.

Authors:  Amanda S Bruegl; Bojana Djordjevic; Brittany Batte; Molly Daniels; Bryan Fellman; Diana Urbauer; Rajyalakshmi Luthra; Charlotte Sun; Karen H Lu; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2014-04-25

Review 9.  [MSI testing : What is new? What should be considered? German version].

Authors:  Josef Rüschoff; Gustavo Baretton; Hendrik Bläker; Wolfgang Dietmaier; Manfred Dietel; Arndt Hartmann; Lars-Christian Horn; Korinna Jöhrens; Thomas Kirchner; Ruth Knüchel; Doris Mayr; Sabine Merkelbach-Bruse; Hans-Ulrich Schildhaus; Peter Schirmacher; Markus Tiemann; Katharina Tiemann; Wilko Weichert; Reinhard Büttner
Journal:  Pathologe       Date:  2021-05-27       Impact factor: 1.011

10.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer.

Authors:  Naohiro Tomita; Hideyuki Ishida; Kohji Tanakaya; Tatsuro Yamaguchi; Kensuke Kumamoto; Toshiaki Tanaka; Takao Hinoi; Yasuyuki Miyakura; Hirotoshi Hasegawa; Tetsuji Takayama; Hideki Ishikawa; Takeshi Nakajima; Akiko Chino; Hideki Shimodaira; Akira Hirasawa; Yoshiko Nakayama; Shigeki Sekine; Kazuo Tamura; Kiwamu Akagi; Yuko Kawasaki; Hirotoshi Kobayashi; Masami Arai; Michio Itabashi; Yojiro Hashiguchi; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2021-06-29       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.